Astellas Pharma's Profit Surges 475% in Fiscal 2025

MT Newswires Live04-27 18:19

Astellas Pharma's (TYO:4503) profit attributable to owners of the parent soared 475% to 291.5 billion yen in fiscal year 2025 from 50.7 billion yen a year earlier.

The pharmaceutical firm's earnings per share increased to 162.22 yen from 28.24 yen a year ago, according to a Tokyo bourse filing on Friday.

Revenue jumped 12% to 2.139 trillion yen in the year ended March 31 from 1.912 trillion yen in the prior year.

During the year, Astellas Pharma booked a 16.4 billion yen impairment loss for intangible assets related to AT132 following a halt in the gene therapy program and a redeployment of resources to ASP2957, the company said in a separate disclosure.

The Japanese firm declared a final dividend of 39 yen per share for fiscal 2025, payable from June 3.

For fiscal 2026, the company expects attributable profit of 300 billion yen, basic EPS of 167.46 yen, and revenue of 2.220 trillion yen.

Astellas plans to pay interim and year-end dividends of 40 yen per share each for the year, which is higher than the amount paid in the year-ago period.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2630367386?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 18:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630367386","market":"hk","top_or_hot":-1,"title":"Astellas Pharma's Profit Surges 475% in Fiscal 2025","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ALPMF\">Astellas Pharma</a>'s (TYO:4503) profit attributable to owners of the parent soared 475% to 291.5 billion yen in fiscal year 2025 from 50.7 billion yen a year earlier.</p><p>The pharmaceutical firm's earnings per share increased to 162.22 yen from 28.24 yen a year ago, according to a Tokyo bourse filing on Friday.</p><p>Revenue jumped 12% to 2.139 trillion yen in the year ended March 31 from 1.912 trillion yen in the prior year.</p><p>During the year, <a href=\"https://laohu8.com/S/ALPMY\">Astellas Pharma</a> booked a 16.4 billion yen impairment loss for intangible assets related to AT132 following a halt in the gene therapy program and a redeployment of resources to ASP2957, the company said in a separate disclosure.</p><p>The Japanese firm declared a final dividend of 39 yen per share for fiscal 2025, payable from June 3.</p><p>For fiscal 2026, the company expects attributable profit of 300 billion yen, basic EPS of 167.46 yen, and revenue of 2.220 trillion yen.</p><p>Astellas plans to pay interim and year-end dividends of 40 yen per share each for the year, which is higher than the amount paid in the year-ago period.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Astellas Pharma's Profit Surges 475% in Fiscal 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstellas Pharma's Profit Surges 475% in Fiscal 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-27 18:19</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ALPMF\">Astellas Pharma</a>'s (TYO:4503) profit attributable to owners of the parent soared 475% to 291.5 billion yen in fiscal year 2025 from 50.7 billion yen a year earlier.</p><p>The pharmaceutical firm's earnings per share increased to 162.22 yen from 28.24 yen a year ago, according to a Tokyo bourse filing on Friday.</p><p>Revenue jumped 12% to 2.139 trillion yen in the year ended March 31 from 1.912 trillion yen in the prior year.</p><p>During the year, <a href=\"https://laohu8.com/S/ALPMY\">Astellas Pharma</a> booked a 16.4 billion yen impairment loss for intangible assets related to AT132 following a halt in the gene therapy program and a redeployment of resources to ASP2957, the company said in a separate disclosure.</p><p>The Japanese firm declared a final dividend of 39 yen per share for fiscal 2025, payable from June 3.</p><p>For fiscal 2026, the company expects attributable profit of 300 billion yen, basic EPS of 167.46 yen, and revenue of 2.220 trillion yen.</p><p>Astellas plans to pay interim and year-end dividends of 40 yen per share each for the year, which is higher than the amount paid in the year-ago period.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FXY","symbol_name":"日元ETF-CurrencyShares","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2630367386","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2630367386","pubTimestamp":1777285164,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Astellas Pharma's  profit attributable to owners of the parent soared 475% to 291.5 billion yen in fiscal year 2025 from 50.7 billion yen a year earlier.The pharmaceutical firm's earnings per share increased to 162.22 yen from 28.24 yen a year ago, according to a Tokyo bourse filing on Friday.Revenue jumped 12% to 2.139 trillion yen in the year ended March 31 from 1.912 trillion yen in the prior year.During the year, Astellas Pharma booked a 16.4 billion yen impairment loss for intangible assets related to AT132 following a halt in the gene therapy program and a redeployment of resources to ASP2957, the company said in a separate disclosure.The Japanese firm declared a final dividend of 39 yen per share for fiscal 2025, payable from June 3.For fiscal 2026, the company expects attributable profit of 300 billion yen, basic EPS of 167.46 yen, and revenue of 2.220 trillion yen.Astellas plans to pay interim and year-end dividends of 40 yen per share each for the year, which is higher than t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FXY":"日元ETF-CurrencyShares","HEWJ":"日本ETF汇率对冲-iShares","YCS":"日元ETF-ProShares两倍做空","YCL":"ProShares Ultra Yen"},"translate_title":"安斯泰来制药2025财年利润飙升475%","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"YCS":0.9,"HEWJ":0.9,"FXY":0.9,"YCL":0.9},"content_text":"Astellas Pharma's (TYO:4503) profit attributable to owners of the parent soared 475% to 291.5 billion yen in fiscal year 2025 from 50.7 billion yen a year earlier.The pharmaceutical firm's earnings per share increased to 162.22 yen from 28.24 yen a year ago, according to a Tokyo bourse filing on Friday.Revenue jumped 12% to 2.139 trillion yen in the year ended March 31 from 1.912 trillion yen in the prior year.During the year, Astellas Pharma booked a 16.4 billion yen impairment loss for intangible assets related to AT132 following a halt in the gene therapy program and a redeployment of resources to ASP2957, the company said in a separate disclosure.The Japanese firm declared a final dividend of 39 yen per share for fiscal 2025, payable from June 3.For fiscal 2026, the company expects attributable profit of 300 billion yen, basic EPS of 167.46 yen, and revenue of 2.220 trillion yen.Astellas plans to pay interim and year-end dividends of 40 yen per share each for the year, which is higher than the amount paid in the year-ago period.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2630367386","isCrawlerRequest":true}